These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

730 related items for PubMed ID: 32317293

  • 1. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
    Lopes JE, Fisher JL, Flick HL, Wang C, Sun L, Ernstoff MS, Alvarez JC, Losey HC.
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
    [Abstract] [Full Text] [Related]

  • 2. Sustained IL-2R signaling of limited duration by high-dose mIL-2/mCD25 fusion protein amplifies tumor-reactive CD8+ T cells to enhance antitumor immunity.
    Hernandez R, Toomer KH, Põder J, Santos Savio A, Hsiung S, Malek TR.
    Cancer Immunol Immunother; 2021 Apr; 70(4):909-921. PubMed ID: 33037893
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer.
    Rosen DB, Kvarnhammar AM, Laufer B, Knappe T, Karlsson JJ, Hong E, Lee YC, Thakar D, Zúñiga LA, Bang K, Sabharwal SS, Uppal K, Olling JD, Kjaergaard K, Kurpiers T, Schnabel M, Reich D, Glock P, Zettler J, Krusch M, Bernhard A, Heinig S, Konjik V, Wegge T, Hehn Y, Killian S, Viet L, Runz J, Faltinger F, Tabrizi M, Abel KL, Breinholt VM, Singel SM, Sprogøe K, Punnonen J.
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35817480
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells.
    Krieg C, Létourneau S, Pantaleo G, Boyman O.
    Proc Natl Acad Sci U S A; 2010 Jun 29; 107(26):11906-11. PubMed ID: 20547866
    [Abstract] [Full Text] [Related]

  • 8. Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2.
    Arenas-Ramirez N, Zou C, Popp S, Zingg D, Brannetti B, Wirth E, Calzascia T, Kovarik J, Sommer L, Zenke G, Woytschak J, Regnier CH, Katopodis A, Boyman O.
    Sci Transl Med; 2016 Nov 30; 8(367):367ra166. PubMed ID: 27903862
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M, Kjaergaard J, Kuppen PJ, Nannmark U, Agger R, Hokland P, Basse P.
    In Vivo; 1999 Nov 30; 13(3):199-204. PubMed ID: 10459491
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells.
    Vazquez-Lombardi R, Loetsch C, Zinkl D, Jackson J, Schofield P, Deenick EK, King C, Phan TG, Webster KE, Sprent J, Christ D.
    Nat Commun; 2017 May 12; 8():15373. PubMed ID: 28497796
    [Abstract] [Full Text] [Related]

  • 13. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
    Dobrzanski MJ, Reome JB, Dutton RW.
    J Immunol; 2001 Jul 01; 167(1):424-34. PubMed ID: 11418679
    [Abstract] [Full Text] [Related]

  • 14. Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate.
    Merchant R, Galligan C, Munegowda MA, Pearce LB, Lloyd P, Smith P, Merchant F, To MD.
    J Immunother Cancer; 2022 Jan 01; 10(1):. PubMed ID: 35058325
    [Abstract] [Full Text] [Related]

  • 15. IL-2Rα mediates temporal regulation of IL-2 signaling and enhances immunotherapy.
    Su EW, Moore CJ, Suriano S, Johnson CB, Songalia N, Patterson A, Neitzke DJ, Andrijauskaite K, Garrett-Mayer E, Mehrotra S, Paulos CM, Doedens AL, Goldrath AW, Li Z, Cole DJ, Rubinstein MP.
    Sci Transl Med; 2015 Oct 28; 7(311):311ra170. PubMed ID: 26511507
    [Abstract] [Full Text] [Related]

  • 16. IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment.
    Desbois M, Béal C, Charrier M, Besse B, Meurice G, Cagnard N, Jacques Y, Béchard D, Cassard L, Chaput N.
    J Immunother Cancer; 2020 Jun 28; 8(1):. PubMed ID: 32532840
    [Abstract] [Full Text] [Related]

  • 17. Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8+ T cells.
    LaPorte KM, Hernandez R, Santos Savio A, Malek TR.
    J Immunother Cancer; 2023 Jun 28; 11(6):. PubMed ID: 37270181
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cutting Edge: Differential Fine-Tuning of IL-2- and IL-15-Dependent Functions by Targeting Their Common IL-2/15Rβ/γc Receptor.
    Meghnem D, Morisseau S, Frutoso M, Trillet K, Maillasson M, Barbieux I, Khaddage S, Leray I, Hildinger M, Quéméner A, Jacques Y, Mortier E.
    J Immunol; 2017 Jun 15; 198(12):4563-4568. PubMed ID: 28507024
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.